With the advent of highly effective antiretroviral therapy (ART), infection with human immunodeficiency virus (HIV) has become a chronic disease rather than a death sentence. Nevertheless, effectively treated individuals have a higher than normal risk for developing noninfectious comorbidities, including cardiovascular and renal disease. Although traditional risk factors of aging as well as treatment toxicity contribute to this risk, many investigators consider chronic HIV-associated inflammation a significant factor in such end-organ disease. Despite effective viral suppression, chronic inflammation persists at levels higher than in uninfected people, yet the stimuli for the inflammation and the mechanism by which inflammation persists and promotes disease pathology remain incompletely understood. This critical gap in scientific understanding complicates and hampers effective decision making about appropriate medical intervention. To better understand the mechanism(s) of chronic immune activation in treated HIV disease, three questions need answers: (1) what is the cause of persistent immune activation during treated HIV infection, (2) what are the best surrogate markers of chronic immune activation in this setting, and (3) what therapeutic intervention(s) could prevent or reverse this process? The NIH sponsored and convened a meeting to discuss the state of knowledge concerning these questions and the best course for developing effective therapeutic strategies. This report summarizes the findings of that NIH meeting.
Get full access to this article
View all access options for this article.
References
1.
AlimontiJB, BallTB, FowkeKR. Mechanisms of CD4+ T lymphocyte cell death in human immunodeficiency virus infection and AIDS. J Gen Virol, July2003; 84,Pt. 7:1649–1661.
2.
MarquesR, WilliamsA, EksmondUet al.Generalized immune activation as a direct result of activated CD4+ T cell killing. J Biol, 2009; 8,10:93.
3.
DoitshG, CavroisM, LassenKGet al.Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. Cell, 2010; 143,5:789–801.
4.
AscherMS, SheppardHW. AIDS as immune system activation: A model for pathogenesis. Clin Exp Immunol, 1988; 73,2:165–167.
5.
HazenbergMD, HamannD, SchuitemakerH, MiedemaF. T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock. Nat Immunol, 2000; 1,4:285–289.
6.
GrossmanZ, HerbermanRB, DimitrovDS. T cell turnover in SIV infection. Science19991999; 284,5414:555.
7.
FaheyJL, TaylorJM, DetelsRet al.The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med, 1990; 322,3:166–172.
8.
GiorgiJV, LiuZ, HultinLEet al.Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr, 1993; 6,8:904–912.
9.
LiuZ, CumberlandWG, HultinLEet al.Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol, 1997; 16,2:83–92.
10.
HuntPW, LandayAL, SinclairEet al.A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers. PLoS One, 2011; 6,1:e15924.
11.
d'EttorreG, PaiardiniM, CeccarelliGet al.HIV-associated immune activation: From bench to bedside. AIDS Res Hum Retroviruses, 2011; 27,4:355–364.
12.
NixonDE, LandayAL. Biomarkers of immune dysfunction in HIV. Curr Opin HIV AIDS, 2010; 5,6:498–503.
13.
ChangKM. Immunopathogenesis of hepatitis C virus infection. Clin Liver Dis, 2003; 7,1:89–105.
14.
La GrutaNL, KedzierskaK, StambasJ, DohertyPC. A question of self-preservation: Immunopathology in influenza virus infection. Immunol Cell Biol, 2007; 85,2:85–92.
15.
SoudeynsH, PantaleoG. The moving target: Mechanisms of HIV persistence during primary infection. Immunol Today, 1999; 20,10:446–450.
16.
KedzierskaK, CroweSM, TurvilleS, CunninghamAL. The influence of cytokines, chemokines and their receptors on HIV-1 replication in monocytes and macrophages. Rev Med Virol, 2003; 13,1:39–56.
17.
AlfanoM, PoliG. Role of cytokines and chemokines in the regulation of innate immunity and HIV infection. Mol Immunol, 2005; 42,2:161–182.
18.
BrownJN, KohlerJJ, CoberleyCRet al.HIV-1 activates macrophages independent of Toll-like receptors. PLoS One, 2008; 3,12:e3664Epub 2008 Dec 2.
19.
OnishiRM, GaffenSL. Interleukin-17 and its target genes: Mechanisms of interleukin-17 function in disease. Immunology, 2010; 129,3:311–321.
20.
MackmanN. The many faces of tissue factor. J Thromb Haemost, 2009; 7,Suppl 1:136–139.
21.
Martínez-MazaO, CrabbE, MitsuyasuRTet al.Infection with the human immunodeficiency virus (HIV) is associated with an in vivo increase in B lymphocyte activation and immaturity. J Immunol, 1987; 138,11:3720–3724.
22.
GiorgiJV, HultinLE, McKeatingJAet al.Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis, 1999; 179,4:859–870.
23.
De MilitoA, NilssonA, TitanjiKet al.Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection. Blood, 2004; 103,6:2180–2186.
24.
El-FarM, HalwaniR, SaidEet al.T-cell exhaustion in HIV infection. Curr HIV/AIDS Rep, 2008; 5,1:13–19.
25.
HazenbergMD, OttoSA, van BenthemBHet al.Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS, 2003; 17,13:1881–1888.
26.
LoriF. Treating HIV/AIDS by reducing immune system activation: The paradox of immune deficiency and immune hyperactivation. Curr Opin HIV AIDS, 2008; 3,2:99–103.
27.
MilushJM, ReevesJD, GordonSNet al.Virally induced CD4+ T cell depletion is not sufficient to induce AIDS in a natural host. J Immunol, 2007; 179,5:3047–3056.
28.
PandreaI, SilvestriG, ApetreiC. AIDS in African nonhuman primate hosts of SIVs: a new paradigm of SIV infection. Curr HIV Res, 2009; 7,1:57–72.
29.
JacquelinB, MayauV, TargatBet al.Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J Clin Invest, 2009; 119,12:3544–3555.
30.
BosingerSE, LiQ, GordonSNet al.Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. J Clin Invest, 2009; 119,12:3556–3572.
31.
KosubDA, LehrmanG, MilushJMet al.Gamma/Delta T-cell functional responses differ after pathogenic human immunodeficiency virus and nonpathogenic simian immunodeficiency virus infections. J Virol, 2008; 82,3:1155–1165.
32.
BrenchleyJM, PaiardiniM. Immunodeficiency lentiviral infections in natural and nonnatural hosts. Blood, 2011; 118:847–854.
33.
LetvinNL, MascolaJR, SunYet al.Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science, 2006; 312,5779:1530–1533.
34.
MattapallilJJ, DouekDC, Buckler-WhiteAet al.Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. J Exp Med, 2006; 203,6:1533–1541.
35.
OkoyeA, Meier-SchellersheimM, BrenchleyJMet al.Progressive CD4+ central memory T cell decline results in CD4+ effector memory insufficiency and overt disease in chronic SIV infection. J Exp Med, 2007; 204,9:2171–2185.
36.
ZengM, SmithAJ, WietgrefeSWet al.Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections. J Clin Invest, 2011; 121,3:998–1008.
37.
BrenchleyJM, DouekDC. HIV infection and the gastrointestinal immune system. Mucosal Immunol, 2008; 1,1:23–30.
38.
d'EttorreG, PaiardiniM, ZaffiriLet al.HIV persistence in the gut mucosa of HIV-infected subjects undergoing antiretroviral therapy correlates with immune activation and increased levels of LPS. Curr HIV Res, 2011; 9,3:148–153.
39.
MartinsonJA, TenorioAR, MontoyaCJet al.Impact of class A, B and C CpG-oligodeoxynucleotides on in vitro activation of innate immune cells in human immunodeficiency virus-1 infected individuals. Immunology, 2007; 120,4:526–535.
40.
ChehimiJ, TrinchieriG. Interleukin-12: a bridge between innate resistance and adaptive immunity with a role in infection and acquired immunodeficiency. J Clin Immunol, 1994; 14,3:149–161.
41.
BoassoA, HerbeuvalJ, HardyAWet al.HIV inhibits CD4+T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells. Blood, 2007; 109,8:3351–3359.
42.
BoassoA, VaccariM, FuchsDet al.Combined effect of antiretroviral therapy and blockade of IDO in SIV-infected rhesus macaques. J Immunol, 2009; 182,7:4313–4320.
43.
BerzinsSP, SmythMJ, BaxterAG. Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol, 2011; 11,2:131–142.
ChomontN, DaFonsecaS, VandergeetenCet al.Maintenance of CD4+T-cell memory and HIV persistence: keeping memory, keeping HIV. Curr Opin HIV AIDS, 2011; 6,1:30–36.
46.
van GrevenyngheJ, ProcopioF, HeZet al.Transcription factor FOXO3a controls the persistence of memory CD4(+) T cells during HIV infection. Nat Med, 2007; 14,3:266–274.
47.
WangC, WenT, RoutyJPet al.4-1BBL induces TNF receptor-associated factor 1-dependent Bim modulation in human T cells and is a critical component in the costimulation-dependent rescue of functionally impaired HIV-specific CD8 T cells. J Immunol, 2007; 179,12:8252–8263.
48.
AzizN, NishanianP, MitsuyasuR, DetelsR, FaheyJL. Variables that affect assays for plasma cytokines and soluble activation markers. Clin Diagn Lab Immunol, 1999; 6,1:89–95.
49.
Kan-MitchellJ, BajczM, SchaubertKLet al.Degeneracy and repertoire of the human HIV-1 Gag p17(77-85) CTL response. J Immunol, 2006; 176,11:6690–6701.
MeierA, ChangJJ, ChanESet al.Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat Med, 2009; 15,8:955–959Epub 2009 Jul 13.
52.
GameiroC, RomaoF. Changes in the immune system during menopause and aging. Front Biosci (Elite Ed), 2010; 2:1299–1303.
53.
MorabitoF, DamleRN, DeaglioSet al.The CD38 ectoenzyme family: advances in basic science and clinical practice. Mol Med, 2006; 12,11–12:342–344.
54.
CaoW, JamiesonBD, HultinLEet al.Regulatory T cell expansion and immune activation during untreated HIV type 1 infection are associated with disease progression. AIDS Res Hum Retroviruses, 2009; 25,2:183–191.
55.
van BaarleD, TsegayeA, MiedemaF, AkbarA. Significance of senescence for virus-specific memory T cell responses: Rapid ageing during chronic stimulation of the immune system. Immunol Lett, 2005; 97,1:19–29.
56.
GordonSN, CervasiB, OdorizziPet al.Disruption of intestinal CD4+ T cell homeostasis is a key marker of systemic CD4+ T cell activation in HIV-infected individuals. J Immunol, 2010; 185,9:5169–5179.
57.
JülgB, GoebelFD. Treatment interruption in HIV therapy: a SMART strategy?Infection, 2006; 34,3:186–188.
58.
FichtenbaumCJ. Inflammatory markers associated with coronary heart disease in persons with HIV infection. Curr Infect Dis Rep, 2011; 13,1:94–101.
59.
EstesJD, HaaseAT, SchackerTW. The role of collagen deposition in depleting CD4+ T cells and limiting reconstitution in HIV-1 and SIV infections through damage to the secondary lymphoid organ niche. Semin Immunol, 2008; 20,3:181–186.
60.
MiricG, DallemagneC, EndreZet al.Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br J Pharmacol, 2001; 133,5:687–694.
61.
MancinoA, LawrenceT. Nuclear factor-kappaB and tumor-associated macrophages. Clin Cancer Res, 2010; 16,3:784–789Epub 2010 Jan 26.
62.
LiX, JiangS, TappingRI. Toll-like receptor signaling in cell proliferation and survival. Cytokine, 2010; 49,1:1–9.
